Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Guided Therapeutics (GTHP) Other Non Operating Income (2016 - 2025)

Guided Therapeutics' Other Non Operating Income history spans 13 years, with the latest figure at -$477000.0 for Q3 2025.

  • For Q3 2025, Other Non Operating Income changed N/A year-over-year to -$477000.0; the TTM value through Sep 2025 reached -$347000.0, down 863.89%, while the annual FY2024 figure was $18000.0, 53.85% down from the prior year.
  • Other Non Operating Income for Q3 2025 was -$477000.0 at Guided Therapeutics, down from $63000.0 in the prior quarter.
  • Across five years, Other Non Operating Income topped out at $448000.0 in Q1 2021 and bottomed at -$477000.0 in Q3 2025.
  • The 5-year median for Other Non Operating Income is $1500.0 (2022), against an average of $9375.0.
  • The largest annual shift saw Other Non Operating Income tumbled 138.96% in 2023 before it soared 9700.0% in 2025.
  • A 5-year view of Other Non Operating Income shows it stood at $147000.0 in 2021, then crashed by 47.62% to $77000.0 in 2022, then crashed by 138.96% to -$30000.0 in 2023, then decreased by 3.33% to -$31000.0 in 2024, then tumbled by 1438.71% to -$477000.0 in 2025.
  • Per Business Quant, the three most recent readings for GTHP's Other Non Operating Income are -$477000.0 (Q3 2025), $63000.0 (Q2 2025), and $98000.0 (Q1 2025).